Ovid Therapeutics Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
OVID$2.850.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| (in thousands, except share and per share data) | June 30,2025 | December 31,2024 |
|---|---|---|
| Assets · (unaudited) | ||
| Current assets: | ||
| Cash and cash equivalents | $28,415 | $26,301 |
| Marketable securities | 9,932 | 26,774 |
| Prepaid expenses and other current assets | 3,742 | 2,865 |
| Total current assets | 42,089 | 55,940 |
| Long-term equity investments | 20,908 | 20,974 |
| Restricted cash | 1,931 | 1,931 |
| Right-of-use asset, net | 12,215 | 12,797 |
| Property and equipment, net | 285 | 433 |
| Other noncurrent assets | — | 92 |
| Total assets | $77,428 | $92,167 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,950 | $3,192 |
| Accrued expenses | 2,872 | 5,994 |
| Current portion, lease liability | 1,384 | 1,336 |
| Deferred revenue | 718 | — |
| Total current liabilities | 8,924 | 10,522 |
| Long-term liabilities: | ||
| Lease liability | 12,715 | 13,419 |
| Total liabilities | 21,639 | 23,941 |
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at June 30, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized; 71,109,514 and 71,009,866 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively | 71 | 71 |
| Additional paid-in-capital | 375,005 | 372,489 |
| Accumulated other comprehensive loss | (69) | (35) |
| Accumulated deficit | (319,218) | (304,299) |
| Total stockholders’ equity | 55,789 | 68,226 |
| Total liabilities and stockholders’ equity | $77,428 | $92,167 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.